The intrinsic pathway of coagulation: A target for treating thromboembolic disease?

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 6, 2007, Pages 1106-1112

  Gailani, David ^a   Renné, Thomas ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Coagulation; Factor XI; Factor XII; Intrinsic pathway; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 9; HEPARIN; PROTEINASE; THROMBOPLASTIN;

ARTERY INJURY; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BLOOD VESSEL OCCLUSION; CAROTID ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME ACTIVITY; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; WILD TYPE;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FACTOR XI; FACTOR XII; HUMANS; MICE; MODELS, CARDIOVASCULAR; THROMBOEMBOLISM; THROMBOPLASTIN;

EID: 34250170510     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02446.x     Document Type: Review

References (67)

1. Kaplan A, Silberberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 1-15.
2. Cochrane CG, Griffin JH. The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 1982; 33: 241-59.
3. Kaplan A, Joseph K, Shibayama Y, Reddigari S, Ghebrehiwet B, Silverberg M. The intrinsic coagulation/kinin-forming cascade: Assembly in plasma and cell surfaces in inflammation. Adv Immunol 1997; 66: 225-72.
4. Colman RW, Schmaier AH. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
5. Macfarlane R. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202: 498-9.
6. Davie E, Ratnoff O. Waterfall sequence for intrinsic clotting. Science 1964; 145: 1310-3.
7. Davie E, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 1991; 30: 10363-70.
8. Rand JH, Senzel L. Laboratory evaluation of hemostatic disorders. In: Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, eds. Hematology: Basic Principles and Practice, 4th edn. New York: Churchill Livingstone, 2005: 2001.
9. Renne T, Gailani D, Meijers J, Muller-Esterl W. Characterization of the H-kininogen-binding site on factor XI: A comparison of factor XI and plasma prekallikrein. J Biol Chem 2002; 277: 4892-9.
10. Lozier JN, Kessler CM. Clinical aspects and therapy of hemophilia. In: Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, eds. Hematology: Basic Principles and Practice, 4th edn. New York: Churchill Livingstone, 2005: 2047.
11. Asakai R, Chung D, Davie E, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Eng J Med 1991; 325: 153-8.
12. Gailani D, Broze GJ. Factor XI and the contact system. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2001: 4433.
13. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
14. Gailani D, Lasky N, Broze G. A murine model of factor XI deficiency. Blood Coag Fibrinol 1997; 8: 134-44.
15. Pauer HU, Renne T, Hemmerlein B, Legler T, Fritzlar S, Adham I, Muller-Esterl W, Emons G, Sancken U, Engel W, Burfeind P. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in.vivo. Thromb Haemost 2004; 92: 503-8.
16. Jiang Y, Doolittle R. The evolution of vertebrate coagulation as viewed from a comparison of puffer fish and sea squirt genomes. Proc Nat Acad Sci USA 2003; 100: 7527-32.
17. Semba U, Shibuya Y, Okabe H, Yamamoto T. Whale Hageman factor (factor XII): Prevented production due to pseudogene conversion. Thromb Res 1998; 90: 31-7.
18. Broze G, Girard T, Novotny W. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochem 1990; 29: 7539-46.
19. Lu G, Broze G, Krishnaswamy S. Formation of factor IXa and Xa by the extrinsic pathway: Differential regulation by tissue factor pathway inhibitor and antithrombin. J Biol Chem 2004; 279: 17241-9.
20. Hathcock JJ, Nemerson Y. Platelet deposition inhibits tissue factor activity: In.vitro clots are impermeable to factor Xa. Blood 2004; 104: 123-7.
21. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-7.
22. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 192-8.
23. Baglia F, Walsh P. Prothrombin is a cofactor for binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin. Biochem 1998; 37: 2271-81.
24. Baglia FA, Walsh PN. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J Biol Chem 2000; 275: 20514-9.
25. Gailani D, Broze G. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
26. von dem Borne P, Meijers J, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
27. Bajzar L, Manuci R, Nesheim M. Purification and characterization of thrombin activatable fibrinolysis inhibitor (TAFI), a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
28. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
29. Keularts I, Zivelin A, Seligsohn U, Hemker H, Beguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001; 85: 1060-5.
30. Cawthern K, van 't Veer C, Lock J, DiLorenzo M, Branda R, Mann K. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
31. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-8.
32. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-81.
33. Kaminishi H, Hamatake H, Cho T, Tamaki T, Suenaga N, Fujii T, Hagihara Y, Maeda H. Activation of blood clotting factors by microbial proteinases. FEBS Microbiol Lett 1994; 121: 347-52.
34. Persson K, Morgelin M, Lindbom L, Alm P, Bjorck L, Herwald H. Severe lung lesions caused by Salmonella are prevented by inhibition of the contact system. J Exp Med 2000; 192: 1415-24.
35. Reddigari S, Shibayama Y, Brunnee T, Kaplan A. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1987; 268: 11982-7.
36. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005; 175: 3377-85.
37. Schmaier A, Rojkjaer R, Shariat-Madar Z. Activation of the plasma/ kallikrein system on cells: A revised hypothesis. Thromb Haemost 1999; 82: 226-33.
38. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 2002; 99: 896-900.
39. Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 2004; 103: 4554-61.
40. Kozik A, Moore RB, Potempa J, Imamura T, Rapala-Kozik M, Travis J. A novel mechanism for bradykinin production at inflammatory sites. Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens. J Biol Chem 1998; 273: 33224-9.
41. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
42. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze Jr GJ, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
43. Furie B, Furie B. Thrombus formation in.vivo. J Clin Invest 2005; 115: 3355-62.
44. Baird TR, Gailani D, Furie B, Furie B. Factor XI deficient mice have reduced platelet accumulation and fibrin deposition after laser injury. Blood 2004; 104: 66a.
45. 3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002; 87: 774-6.
46. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-8.
47. Choudhri T, Hih B, Prestigiacomo C, Huang J, Kim L, Schmidt A, Kisiel W, Connolly E, Pinsky D. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med 1999; 190: 91-9.
48. Heemskerk J, Bevers E, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-93.
49. Walsh PN, Griffin JH. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 1981; 57: 106-18.
50. Johne J, Blume C, Benz PM, Pozgajova M, Ullrich M, Schuh K, Nieswandt B, Walter U, Renne T. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem 2006; 387: 173-8.
51. Meijers J, Tekelenburg W, Bouma B, Bertina R, Rosendaal F. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
52. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men. Opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
53. Salomon O, Steinberg D, Dardik R, Rosenberg N, Zivelin A, Tamarin I, Ravid B, Berliner S, Seligsohn U. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003; 1: 658-61.
54. Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126: 411-5.
55. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In.vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
56. Yamashita A, Nishihira K, Kitazawa T, Yoshihashi K, Soeda T, Esaki K, Imamura T, Hattori K, Asada Y. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost 2006; 4: 1496-501.
57. Gruber A, Hanson S. Factor XI-dependence of surface- and tissue factor-initiated thrombus formation in primates. Blood 2003; 102: 953-5.
58. Ratnoff OD. The George M. Kober lecture. The legacy of John Hageman: New dividends. Trans Assoc Am Physicians 1985; 98: 151-61.
59. Koster T, Rosendaal FR, Briet E, Vandenbroucke JP. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br J Haematol 1994; 87: 422-4.
60. Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M, Lammle B. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency-a study on 73 subjects from 14 Swiss families. Thromb Haemost 1999; 82: 1240-6.
61. Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: A study of prevalence in 21 Patients and review of the literature. J Thromb Thrombolysis 2004; 17: 139-43.
62. Miller G, Esnouf M, Burgess A, Cooper J, Mitchell J. Risk of coronary heart disease and activation of factor XII in middle aged men. Arterisocler Thromb Vasc Biol 1997; 17: 2103-6.
63. Grundt H, Nilsen D, Hetland O, Valente E, Fagertun H. Activated factor XII (FXIIa) predicts recurrent coronary events after acute myocardial infarction. Am Heart J 2004; 147: 260-6.
64. Endler G, Marsik C, Schickbauer T, Jilma B, Quehenberger P, Wagner O, Mannhalter C. Plasma activity of coagulation factor XII and all cause mortality in Vienna (ACMIV study) -evidence of a J-shaped association of factor XII activity and overall survival. Hämostasiologie 2006; 26: A30.
65. Cheng Q, Zhao Y, Lawson WE, Polosukhin VV, Johnson JE, Blackwell TS, Gailani D. The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice. Blood 2005; 106: 3055-7.
66. Bugge T, Flick M, Daugherty C, Degen J. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Develop 1995; 9: 794-807.
67. Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Path 2000; 157: 177-87.